Loading people...
Lorence Kim is the Co-founder and Managing Partner of Ascenta Capital, a New York City biotechnology venture capital firm formed in 2022. Before working as a Venture Partner at Third Rock Ventures, he served as Chief Financial Officer at Moderna from 2014 to 2020. During this tenure, he successfully raised $4.4 billion and advanced 24 development candidates, including the COVID-19 vaccine. He previously spent fourteen years at Goldman Sachs as co-head of United States biotechnology investment banking, overseeing $55 billion in mergers and acquisitions. Kim holds an MD and an MBA from the University of Pennsylvania, earned his undergraduate degree from Harvard University, and serves on the boards of Revolution Medicines, Cencora, and the American Red Cross. His current investments focus on funding early-stage companies developing novel therapeutics for infectious, autoimmune, and rare diseases.
Lorence Kim stands as a pivotal Venture Partner at Third Rock Ventures, a renowned venture capital firm celebrated for its unique approach to company creation within the life sciences sector. In this influential role, Lorence is deeply involved in the entire lifecycle of building transformative biotech companies, from identifying nascent scientific breakthroughs to providing strategic guidance for their growth and success. His expertise is crucial in shaping the next generation of therapeutic solutions and healthcare innovations.
At Third Rock Ventures, Loreence Kim's investment focus aligns with the firm's mission to launch and nurture companies that address significant unmet medical needs. He is particularly interested in novel drug discovery platforms, groundbreaking therapeutic modalities, and innovative approaches to patient care across various disease areas. His strategic insights help portfolio companies navigate complex scientific, clinical, and financial landscapes, ensuring they are well positioned to bring life changing medicines to patients.
Lorence's distinguished career background provides a robust foundation for his contributions at Third Rock Ventures. Most notably, he served as the Chief Financial Officer (CFO) of Moderna, Inc., a pioneering biotechnology company that became a household name for its mRNA vaccine technology. During his tenure at Moderna, Lorence was instrumental in scaling the company's financial operations, guiding its significant growth, and playing a key role in its successful initial public offering (IPO). This experience equipped him with invaluable insights into the operational and financial intricacies of rapidly expanding biotech ventures.
Prior to Moderna, Lorence Kim honed his financial acumen and strategic leadership skills through various roles in the healthcare and finance sectors. His experience includes positions at leading financial institutions like Goldman Sachs, where he gained extensive knowledge in investment banking and capital markets. This blend of deep financial expertise and hands on operational leadership within a high growth biotech environment makes him an exceptionally valuable asset to Third Rock Ventures and its portfolio companies. He leverages this diverse background to help founders and management teams build robust business models, secure funding, and execute ambitious scientific and clinical development plans. While Third Rock Ventures primarily creates companies internally rather than making traditional external investments, Lorence Kim's involvement is critical in the formation and strategic development of these new ventures, guiding them from concept to impactful enterprises.
Lorence Kim is a distinguished Venture Partner at Third Rock Ventures, a leading life sciences venture capital firm. He is widely recognized for his extensive experience in biotech leadership and finance, notably serving as the former Chief Financial Officer of Moderna, Inc.
As a Venture Partner at Third Rock Ventures, Lorence Kim is instrumental in identifying, building, and guiding new companies focused on groundbreaking scientific discoveries in the life sciences. His focus areas include novel therapeutics, drug discovery, and platform technologies addressing significant unmet medical needs.
Lorence Kim works at Third Rock Ventures, a leading venture capital firm dedicated to building innovative life science companies. The firm has offices in Boston, MA, and San Francisco, CA.
